Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 25;15(9):1431-1442.
doi: 10.1093/ecco-jcc/jjab050.

Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

Bram Verstockt  1   2 , Nurulamin M Noor  3   4 , Urko M Marigorta  5   6 , Polychronis Pavlidis  7   8 , Parakkal Deepak  9 , Ryan C Ungaro  10 ; Scientific Workshop Steering Committee
Collaborators, Affiliations
Review

Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

Bram Verstockt et al. J Crohns Colitis. .

Abstract

Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.

Keywords: Precision medicine; disease outcome; disease prognosis; inflammatory bowel diseases; personalised medicine; response to therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Utility of prognostic and predictive biomarkers along the inflammatory bowel disease [IBD] patient’s journey. Published with permission from ©Mount Sinai Health System.
See this image and copyright information in PMC

References

    1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet 2017;389:1741–55. - PubMed
    1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2017;389:1756–70. - PMC - PubMed
    1. Fiocchi C, Dragoni G, Iliopoulos D, et al. Results of the seventh scientific workshop of the ECCO: precision medicine in IBD— what, why and how. J Crohns Colitis 2021. PMID: 33733656.
    1. Torres J, Halfvarson J, Rodriguez-Lago I, et al. Results of the seventh scientific workshop of ECCO: prediction and prevention of inflammatory bowel diseases. J Crohns Colitis 2021. PMID: 33730755. - PubMed
    1. FDA-NIH Biomarker Working Group. Best [biomarkers, endpoints, and other tools] resource.2016. https://www.ncbi.nlm.nih.gov/books/NBK326791/. Accessed 15 November 2020.